应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
IBB 生物科技指数ETF-iShares Nasdaq
盘前交易 07-31 04:55:24 EDT
189.96
+1.43
+0.76%
盘前
191.82
+1.86
+0.98%
04:42 EDT
最高
190.18
最低
185.75
成交量
184.69万
今开
186.49
昨收
188.53
日振幅
2.35%
总市值
94.03亿
流通市值
94.03亿
总股本
4,950万
成交额
3.47亿
换手率
3.73%
流通股本
4,950万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
赛诺菲预期研发支出将温和增长
投资观察 · 07-30 20:55
赛诺菲预期研发支出将温和增长
再生元制药Q2调整后每股收益14.29美元，远超IBES预期10.3美元
投资观察 · 07-30 18:50
再生元制药Q2调整后每股收益14.29美元，远超IBES预期10.3美元
AbCellera Biologics获2800万美元预付款及里程碑付款与阶梯式版税
美股速递 · 07-29 19:06
AbCellera Biologics获2800万美元预付款及里程碑付款与阶梯式版税
AbCellera携手福泰制药，共同开发针对自身免疫疾病的多特异性T细胞接合器
美股速递 · 07-29 19:01
AbCellera携手福泰制药，共同开发针对自身免疫疾病的多特异性T细胞接合器
解读世界500强榜单医药板块：强生继续“霸榜”，礼来排名上升112位，3家中国企业入选
每日经济新闻 · 07-28 20:51
解读世界500强榜单医药板块：强生继续“霸榜”，礼来排名上升112位，3家中国企业入选
Bitget 已上线 SKDD、GILD、TMF 等 9 只股票永续合约
链捕手 · 07-28
Bitget 已上线 SKDD、GILD、TMF 等 9 只股票永续合约
Argenx(ARGX.US)豪掷22亿美元、溢价40%收购Forte Biosciences(FBRX.US) 加码布局免疫学药物组合
智通财经 · 07-27
Argenx(ARGX.US)豪掷22亿美元、溢价40%收购Forte Biosciences(FBRX.US) 加码布局免疫学药物组合
吉利德科学(GILD)肿瘤组合疗法获欧洲药品管理局旗下CHMP推荐
金吾财讯 · 07-24
吉利德科学(GILD)肿瘤组合疗法获欧洲药品管理局旗下CHMP推荐
CHMP推荐吉利德Trodelvy®联合Keytruda®用于PD-(L)1阳性一线转移性三阴性乳腺癌
美股速递 · 07-24
CHMP推荐吉利德Trodelvy®联合Keytruda®用于PD-(L)1阳性一线转移性三阴性乳腺癌
百济神州/安进 FIC 双抗，皮下制剂进入 III 期
新浪医药 · 07-23
百济神州/安进 FIC 双抗，皮下制剂进入 III 期
argenx(ARGX)二季度产品净销售额达15.16亿美元 同比增长60%
金吾财讯 · 07-23
argenx(ARGX)二季度产品净销售额达15.16亿美元 同比增长60%
创新药研发加速遇“猴荒”
三里河 · 07-22
创新药研发加速遇“猴荒”
Leerink Partners下调吉利德科学评级至“与大盘持平”，目标价大幅调降至127美元
美股速递 · 07-21
Leerink Partners下调吉利德科学评级至“与大盘持平”，目标价大幅调降至127美元
Leerink下调吉利德科学目标价至127美元
格隆汇 · 07-21
Leerink下调吉利德科学目标价至127美元
三星生物制剂与欧加农将在澳大利亚推出新型生物类似药。
智通财经 · 07-16
三星生物制剂与欧加农将在澳大利亚推出新型生物类似药。
Vertex(VRTX)百亿美元收购罕见病药企 拓宽内分泌管线布局
金吾财讯 · 07-13
Vertex(VRTX)百亿美元收购罕见病药企 拓宽内分泌管线布局
Pliant Therapeutics任命Flavia Borellini博士和Robert Iannone博士加入董事会
投资观察 · 07-13
Pliant Therapeutics任命Flavia Borellini博士和Robert Iannone博士加入董事会
英硅智能早盘涨超7% 与康哲药业达成AI+创新药研发新合作
新浪港股 · 07-13
英硅智能早盘涨超7% 与康哲药业达成AI+创新药研发新合作
福泰制药百亿美元并购透露了什么讯号？
蓝鲸财经 · 07-11
福泰制药百亿美元并购透露了什么讯号？
大摩解读福泰制药百亿收购Crinetics：补齐内分泌管线布局 两大核心药物打开增长空间
智通财经 · 07-08
大摩解读福泰制药百亿收购Crinetics：补齐内分泌管线布局 两大核心药物打开增长空间
加载更多
公司概况
公司名称：
生物科技指数ETF-iShares Nasdaq
所属市场：
NASDAQ
上市日期：
--
主营业务：
安硕纳斯达克生物科技ETF追踪纳斯达克生物医疗指数(Biotechnology Index)。Biotechnology Index包含的标的为在纳斯达克上市的生物医疗公司。 风险提示：标的成分和权重，有可能随着时间的迁移而发生变化。
发行价格：
--
{"stockData":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"生物科技指数ETF-iShares Nasdaq","latestPrice":189.96,"timestamp":1785441600000,"preClose":188.53,"halted":0,"volume":1846938,"hourTrading":{"tag":"盘前","latestPrice":191.8164,"preClose":189.96,"latestTime":"04:42 EDT","volume":125,"amount":23950.125,"timestamp":1785487368384,"change":1.8564,"changeRate":0.009773,"amplitude":0.020322},"delay":0,"changeRate":0.007584999734790255,"floatShares":49500000,"shares":49500000,"eps":6.311863,"marketStatus":"盘前交易","change":1.43,"latestTime":"07-31 04:55:24 EDT","open":186.485,"high":190.18,"low":185.7471,"amount":347102039.76564,"amplitude":0.023513,"askPrice":191.96,"askSize":300,"bidPrice":190.59,"bidSize":1,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785504600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":189.96,"sharesOutstanding":50050000,"nav":188.641989,"aum":9318914256.6,"dividendRate":0.0022,"bidAskSpread":0.000504,"preHourTrading":{"tag":"盘前","latestPrice":191.8164,"preClose":189.96,"latestTime":"04:42 EDT","volume":125,"amount":23950.125,"timestamp":1785487368384,"change":1.8564,"changeRate":0.009773,"amplitude":0.020322},"postHourTrading":{"tag":"盘后","latestPrice":187.89,"preClose":189.96,"latestTime":"19:34 EDT","volume":34746,"amount":6534455.1632,"timestamp":1785454450103,"change":-2.07,"changeRate":-0.010897,"amplitude":0.013161},"volumeRatio":1.4515390523126819,"impliedVol":0.2213,"impliedVolPercentile":0.388},"requestUrl":"/m/hq/s/IBB","defaultTab":"news","newsList":[{"id":"1150899419","title":"赛诺菲预期研发支出将温和增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1150899419","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150899419?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:55","pubTimestamp":1785416128,"startTime":"0","endTime":"0","summary":"赛诺菲首席执行官Belen Garijo在分析师电话会议上表示，预计中期内公司的研发支出将呈现温和增长态势。同时，Garijo强调：“我们必须迎头赶上，并充分利用中国正在涌现的创新浪潮。”然而，他同时指出，赛诺菲在中国的战略可能不会完全复制其全球战略。此外，赛诺菲方面明确，与再生元制药公司的合作并非公司推进并购交易的障碍。一位赛诺菲高管还透露，预计Dupixent的专利保护期将持续到2031年3月之后。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","LU2362541273.HKD","LU0320765992.SGD","LU2089984988.USD","BK4585","LU0882574055.USD","LU1974910355.USD","LU0823434583.USD","LU0053666078.USD","LU2106854487.HKD","LU2237438978.USD","LU2468319806.SGD","LU0109394709.USD","LU1917777945.USD","LU0289739699.SGD","LU0889565916.HKD","REGN","LU0823434740.USD","IBB","LU2362541513.USD","LU0823416689.USD","LU2023250504.SGD","TBXU","LU0058720904.USD","LU0114720955.EUR","LU2362540622.SGD","BBH","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149696560","title":"再生元制药Q2调整后每股收益14.29美元，远超IBES预期10.3美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149696560","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149696560?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:50","pubTimestamp":1785408636,"startTime":"0","endTime":"0","summary":"再生元制药第二季度营收达到42.91亿美元，显著高于IBES预估的38.16亿美元。这一强劲表现不仅体现在营收端，更反映在盈利能力上——公司调整后的每股收益为14.29美元，远高于市场预期的10.3美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","LU2362541513.USD","BK4585","LU2023250504.SGD","LU0109394709.USD","REGN","IBBQ","LU0889565916.HKD","LU2237438978.USD","LU2468319806.SGD","IBB","LU2362541273.HKD","LU0053666078.USD","LU1974910355.USD","LU0882574055.USD","BK4588","TBXU","LU0823416689.USD","LU0289739699.SGD","LU0823434583.USD","LU2089984988.USD","LU0320765992.SGD","LU0823434740.USD","LU2362540622.SGD","LU2106854487.HKD","LU1917777945.USD","LU0114720955.EUR","LU0058720904.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185330982","title":"AbCellera Biologics获2800万美元预付款及里程碑付款与阶梯式版税","url":"https://stock-news.laohu8.com/highlight/detail?id=1185330982","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185330982?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:06","pubTimestamp":1785323188,"startTime":"0","endTime":"0","summary":"AbCellera Biologics公司宣布，将收到一笔高达2800万美元的预付款。除此之外，还有里程碑付款以及阶梯式特许权使用费加持。这笔交易架构颇为复杂，既有前期现金注入，也有后续潜在收益。预付款即刻到账，为研发管线提供弹药。里程碑款项则与特定项目进展挂钩，分期兑现。至于阶梯式版税，会随着产品销售额的攀升而逐步增加。整体来看，这一支付安排既保障了短期资金流，又锁定了长期回报空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNMX","IE00BZ9MQY76.HKD","LU2237438978.USD","IE00BFTCPJ56.SGD","SG9999013999.USD","SGXZ57979304.SGD","IDNA","SG9999001176.SGD","BK4121","IE0009355771.USD","LU2236285917.USD","LU1093756325.SGD","IE00B19Z3B42.SGD","LU0079474960.USD","LU2456880835.USD","LU2417539215.USD","LU2324357040.USD","IBBQ","IE00B2B36J28.USD","ABCL","IBB","LU0256863811.USD","LU1093756168.USD","IE00B19Z9Z06.USD","LU2362541273.HKD","BK4588","PBE","TBXU","LU0061475181.USD","IE00B19Z9P08.USD","LU0289739699.SGD","IE00B19Z3581.USD","LU0432979614.USD","LU2362541513.USD","IE0002270589.USD","LU2362540622.SGD","BBH","BK4532","LU2462157665.USD","LU1069344957.HKD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00B894F039.SGD","LU1674673428.USD","IE0002141913.USD","IE00B4R5TH58.HKD","LU0417517546.SGD","BK4535","LU0058720904.USD","IE00BJT1NW94.SGD","LU1674673691.USD","LU1035775433.USD","LU1778281490.HKD","BIB","LU0234570918.USD","LU1585245621.USD","VRTX","LU0823416689.USD","BK4567","LU0889565916.HKD","LU1430594728.SGD","BK4533","SG9999001176.USD","BK4139","LU0320765992.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147206442","title":"AbCellera携手福泰制药，共同开发针对自身免疫疾病的多特异性T细胞接合器","url":"https://stock-news.laohu8.com/highlight/detail?id=1147206442","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147206442?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:01","pubTimestamp":1785322903,"startTime":"0","endTime":"0","summary":"AbCellera宣布与福泰制药达成合作，旨在共同探索和发现针对自身免疫性疾病及其他适应症的多特异性T细胞接合器。这一战略合作将结合双方的技术优势，致力于在治疗领域开拓创新路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","LU0289739699.SGD","IE00B19Z9Z06.USD","IE0002141913.USD","BK4121","LU1093756168.USD","LU1069344957.HKD","BIB","IE00BJJMRZ35.SGD","LU0234570918.USD","LU0889565916.HKD","BK4533","LU0320765992.SGD","LU1035775433.USD","SG9999001176.SGD","LU0823416689.USD","BK4532","ABCL","IE00BZ9MQY76.HKD","LU2462157665.USD","IBBQ","SG9999013999.USD","BK4585","BBH","BK4535","IBB","LU2236285917.USD","LU2362540622.SGD","VRTX","IE00B19Z3581.USD","LU0256863811.USD","IDNA","IE00B19Z3B42.SGD","BK4139","LU0061475181.USD","LU2324357040.USD","LU0058720904.USD","IE0009355771.USD","TBXU","BK4588","IE00B894F039.SGD","IE00BJT1NW94.SGD","LU2456880835.USD","LU2362541513.USD","LU0079474960.USD","LU0109394709.USD","LU2237438978.USD","IE00B19Z9P08.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0432979614.USD","LU1674673691.USD","LU1674673428.USD","LU1093756325.SGD","IE00BFTCPJ56.SGD","LU2362541273.HKD","LU1585245621.USD","SG9999001176.USD","LU0417517546.SGD","GNMX","LU1778281490.HKD","IE0002270589.USD","PBE","SGXZ57979304.SGD","LU2417539215.USD","BK4567"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654007935","title":"解读世界500强榜单医药板块：强生继续“霸榜”，礼来排名上升112位，3家中国企业入选","url":"https://stock-news.laohu8.com/highlight/detail?id=2654007935","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654007935?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:51","pubTimestamp":1785243108,"startTime":"0","endTime":"0","summary":"7月28日，2026年《财富》世界500强榜单正式发布。《每日经济新闻》记者注意到，医疗健康板块作为全球五大支柱行业之一，共有31家企业上榜。其中，礼来公司排名从2025年的336位上升至今年的224位，成为今年上涨最快的10家公司之一。中国公司中，中国医药集团、上海医药、广药集团3家公司再次入围。《每日经济新闻》记者注意到，位居医疗健康相关企业榜首的是联合健康集团。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607283823749452.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607283823749452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["VHT","BK4139","LU0792757196.USD","LU1043141123.HKD","NVO","UNHU","BK4532","LU0795875086.SGD","IE00BN8TJ469.HKD","LU0321505868.SGD","LU0211328371.USD","LU0203202063.USD","LU2023250504.SGD","LU2471134796.USD","IE0002270589.USD","LU2106854487.HKD","LU1069344957.HKD","GDOC","IE0005OL40V9.USD","SG9999014880.SGD","LU2133065610.SGD","LU2361045086.USD","LU0225771236.USD","LU2089283258.USD","LU1066053197.SGD","LU2552382058.USD","LU2552382132.HKD","PJP","LU2087621335.USD","IE0000B7K699.USD","IE00BLSP4452.SGD","PBE","LU0114720955.EUR","LU0128525689.USD","MHIP","SG9999014567.USD","LU2462591277.SGD","LU0187121727.USD","LU0158827948.USD","LU2417539215.USD","LU0353189763.USD","LU1267930730.SGD","LU2552382215.SGD","SGXZ51526630.SGD","LU1496350171.SGD","IE00BVYPNW00.USD","LU2362541273.HKD","LU0395794307.EUR","LU1989771016.USD","LU0976567544.SGD","TMED","LU1064131342.USD","LU2471134879.HKD","LU1804176565.USD","LU2491050154.USD","IE0004445239.USD","LU2468319806.SGD","LU1712237335.SGD","LU2237443549.SGD","SG9999001176.SGD","LU1244550221.USD","BK4599","LU0385154629.USD","LU0211326755.USD","LU1868836591.USD","LU0417517546.SGD","SG9999015978.USD","LU0011850046.USD","SG9999002224.SGD","LU1430594728.SGD","ELIS","LU0048584097.USD","LU0345770993.USD","LU0672654240.SGD","LU2357627491.SGD","LU1934455863.HKD","LU0096364046.USD","IE00BJJMRZ35.SGD","LLYZ","LU0130102774.USD","LU0006306889.USD","IE000SO60NU8.SGD","LU0345769631.USD","LU2487616109.SGD","LU0859254822.USD","LU0354030438.USD","LU1221951046.USD","LU0823416689.USD","LU0912757837.SGD","LU1043141396.HKD","LU2237443465.HKD","IE00BKVL7J92.USD","03165","LU2505996509.AUD","LU1232071149.USD","LU0266013472.USD","LU2242649171.HKD","IE00B19Z8X17.USD","LU1057294990.SGD","LU1291159041.SGD","LU2461242641.AUD","SG9999001176.USD","LU2089984988.USD","LU0310800965.SGD","LU1069347547.HKD","IE0001KFT4U8.USD","IE00BZ9MQY76.HKD","LU0980610538.SGD","ELIL","LU0265550946.USD","ILDR","LU2279689827.SGD","LU0162691827.USD","SG9999017495.SGD","IE00B4R5TH58.HKD","LU1201861249.SGD","BK4154","BMED","LU0058720904.USD","BK4559","LU0053666078.USD","LU0477156953.USD","TBXU","LU0320765992.SGD","MEDX","GB00BDT5M118.USD","LU1988902786.USD","04332","LU2756315664.SGD","LU1894683264.USD","LU1941712264.USD","LU1883839398.USD","IE00BKDWB100.SGD","LU1571399168.USD","SGXZ57979304.SGD","LU2129689605.HKD","XLV","LU0985481810.HKD","LU1228905540.USD","LU2237443895.HKD","PPH","LU2023250843.SGD","LU0225284248.USD","LU1623119135.USD","LU2237438978.USD","LU1699723380.USD","LU0098860793.USD","LU0251132253.USD","GLAM","AGNG","LU0868494617.USD","IE00BWXC8680.SGD","LU1119994496.HKD","LU0965509010.AUD","BK4007","BIB","LU1720051108.HKD","LU0882574139.USD","LU0545039389.USD","LU0323591593.USD","SG9999014914.USD","LU1035775433.USD","NVS","AMGN","IXJ","LU1032466523.USD","IE00BJT1NW94.SGD","OZEM","LU2746668974.SGD","LU1935042991.SGD","LU1778281490.HKD","LU0256863902.USD","IE000BZT7R73.USD","LU0882574055.USD","SG9999001440.SGD","LU0795875169.SGD","IE00BN29S564.USD","LU2111349929.HKD","LU1839511570.USD","IE000F7OJYX1.SGD","LU2592432038.USD","SG9999014575.USD","LU1854103824.USD","LU0426417589.USD","SG9999015986.USD","LU2347655156.SGD","LU1934455277.USD","IE000M9KFDE8.USD","LU1261432733.SGD","BK4578","IE0009355771.USD","IE00B894F039.SGD","RHHBY","LU1914381329.SGD","LU1923622614.USD","LU1116320737.USD","LU1061106388.HKD","LU2237443622.USD","LU1121112475.USD","LU1629891620.HKD","LU0345769128.USD","LU1551013425.SGD","LU2271345857.HKD","LU0553294199.USD","LU0211327993.USD","LU1989772840.SGD","LU2756315318.SGD","LU2213496289.HKD","LU0310800379.SGD","LU0234570918.USD","LU2430703251.USD","SG9999018857.SGD","IBB","LU0456855351.SGD","LU1983299246.USD","LU2168564149.EUR","LU0820561909.HKD","IE00BZ1G4Q59.USD","IE00B42XCP33.USD","LU2089284900.SGD","LU2087625088.SGD","LU2242646821.SGD","LU2063271972.USD","BK4550","LU1868837300.USD","LU1670628061.USD","LU0198837287.USD","LU0238689110.USD","IE00BBT3K403.USD","LU0057025933.USD","LU0823434583.USD","LU1868837136.USD","SGXZ81514606.USD","LU1267930490.SGD","LU2361044865.SGD","LU0310799852.SGD","LU1003077747.HKD","JNJ","WDNA","LU1929549753.HKD","IE00B775H168.HKD","LU1496350502.SGD","LU1267930573.SGD","IE00B19Z3581.USD","IHE","LU0471298694.HKD","BK4504","IE00BVYPNV92.GBP","LU0225283273.USD","LU0965509101.SGD","LU0070302665.USD","LU0342679015.USD","LU1093756325.SGD","IBBQ","LU1267930227.SGD","LLYX","LU2108987350.USD","LU2168564495.EUR","LU2237443382.USD","LU0069063385.USD","SGXZ99366536.SGD","IE00B4JS1V06.HKD","IE00B19Z9P08.USD","LU1116320901.HKD","LU0994945656.USD","BK4585","LU1868836757.USD","LU0661504455.SGD","LU0077335932.USD","LU2244417387.USD","LU1585245621.USD","LU2360032135.SGD","LU1791710400.SGD","IE00BKPKM429.USD","LU2403377893.USD","UNHG","LU0471298777.SGD","NVOX","IE00BJJMRX11.SGD","LU1718418525.SGD","IE00B3PB1722.GBP","BK4516","LU1074936037.SGD","LU0149725797.USD","LU0557290698.USD","LU2362541513.USD","LU2471134523.USD","LU0203345920.USD","LU2242652126.USD","LU2462591350.SGD","MRK","LU1221951129.SGD","LU0861579265.USD","CANC","LLY","LU0122379950.USD","LU1917777945.USD","LU2596442595.SGD","LU0203201768.USD","LU0128525929.USD","LU0426412945.USD","LU2750360641.GBP","RXL","LU2430703178.SGD","LU0320765059.SGD","LU1941712348.USD","BK4533","LU2462157665.USD","LU0306806265.USD","IE00B7KXQ091.USD","LU1674673428.USD","LU1127390331.HKD","LU2896262040.SGD","LU2999663052.SGD","IE00BFTCPJ56.SGD","LU1894683348.USD","LU0097036916.USD","IE00BJJMRY28.SGD","LU0820562030.AUD","LU1791710582.SGD","LU2433249047.HKD","UNHW","JDOC","LU1035773651.USD","SG9999002232.USD","LU0029864427.USD","LU1548497426.USD","LU0265550359.USD","IE000MB6IJN5.SGD","LU1066051225.USD","LU1868836914.USD","LU2491049909.HKD","PAWZ","LU2430703095.HKD","TRUH","IHF","LU1670627923.USD","LU0306807586.USD","LU1267930813.SGD","LU2236285917.USD","LU0965508806.USD","LU1153585028.USD","LU0943347566.SGD","NVOH","LU0466842654.USD","LU0107464264.USD","SG9999015945.SGD","IE00B19Z9Z06.USD","SG9999011175.SGD","IE00BSNM7G36.USD","FTXH","LU0964807845.USD","SG9999013999.USD","LU1989772923.USD","LU1974910355.USD","BK4592","LU0432979614.USD","LU0942090050.USD","SG9999015952.SGD","IE0002141913.USD","LU0203347892.USD","FHLC","LU0823434740.USD","LU0211326839.USD","LU2347655073.USD","LU2129689431.USD","LU1162221912.USD","LLII","LU0889565916.HKD","LU0648001328.SGD","LU1506573853.SGD","SG9999015341.SGD","LU0289739343.SGD","LU1674673691.USD","IE00B7SZLL34.SGD","LU0683600562.USD","LU0256863811.USD","LU0738911758.USD","LU2750360997.AUD","LU0052756011.USD","HRTS","LU2265009873.SGD","LU0079474960.USD","LU1037948897.HKD","BK4588","IYH","IE000WAW04H5.SGD","IE00BK4W5L77.USD","LU0070217475.USD","IE00BK4W5M84.HKD","LU1032955483.USD","LU1934455194.USD","LU0061475181.USD","LU0174119429.USD","LU1244550494.USD","LU2125909593.SGD","IE00BGHQF631.EUR","LU2129689514.USD","LU0133085943.USD","LU1084165304.USD","PFE","LU1093756168.USD","LU0708994859.HKD","SGXZ31699556.SGD","LU1323610961.USD","LU2028103732.USD","SG9999014542.SGD","IE0034235303.USD","LU0496365809.HKD","LU1066051811.HKD","LU2264538146.SGD","LU1732799900.SGD","IE00BFSS8Q28.SGD","LU1228905037.USD","UNH","LU1059921491.USD","IE00BJLML261.HKD","LU0124676726.USD","LU2168563687.JPY","LU2360106947.USD","LU0353189680.USD","LU0109394709.USD","LU1196500208.SGD","LU0472753341.HKD","LU2471134952.CNY","SG9999018865.SGD","LU0868494708.USD","BK4581","LU2456880835.USD","IE00B1BXHZ80.USD","LU1814569148.SGD","LU0154236417.USD","THNR","IE00BFSS7M15.SGD","LU2746668461.USD","SG9999014898.SGD","LU0949170772.SGD","LU0109391861.USD","LU0889566641.SGD","IE00BLSP4239.USD","LU1023059063.AUD","LU0545562505.USD","LU0786609619.USD","LU0143551892.USD","LU0345770308.USD","SG9999015358.SGD","LU1066051498.USD","LU2237443978.SGD","LU2491050071.SGD","LU0320765489.SGD","BK4566","LU2324357040.USD","LU0820561818.USD","BK4568","IE00BFXG1179.USD","SG9999014906.USD","LU0689472784.USD","LU0094547139.USD","SG9999003800.SGD","IE00B2B36J28.USD","LU0787776722.HKD","LU1280957306.USD","LU1145028129.USD","LU2125154778.USD","LU0211331839.USD","LU0208291251.USD","LU0289961442.SGD","IE00B3T34201.USD","CURE","IE00B19Z9505.USD","LU0640476718.USD","LU0985320562.USD","IE00B1XK9C88.USD","LU2361044949.HKD","LU0170899867.USD","LU0072461881.USD","LU0528227936.USD","LU2125909247.SGD","LU1720051017.SGD","ABBV","LU0965509283.SGD","LU2211815571.USD","LU0130517989.USD","LU0234572021.USD","LU1037948541.HKD","LU0354030511.USD","BK4534","MEDI","LU2125154935.USD","IE00B19Z8W00.USD","LU0511384066.AUD","LU0708995401.HKD","LU1366192091.USD","LU1244550577.SGD","LU0289739699.SGD","LU2168564222.USD","LU2357305700.SGD","LU0316494557.USD","IE00B19Z3B42.SGD","BBH","LU1854104046.USD","LU2168564065.EUR","LU2954938101.SGD","IE00BDGV0183.EUR","LU0321505439.SGD","LU2505996681.GBP","LU0158827781.USD","LU2112291526.USD","LU0726765562.USD","LU1551013342.USD","LU2023250330.USD","IE0004445015.USD","LU2602419157.SGD","LU0106261372.USD","LU1732800096.USD","LU0320765646.SGD","SG9999014559.SGD","LU0210528500.USD","LU0689626769.HKD","LU0210536198.USD","LU2362540622.SGD","LU2023251221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654027040","title":"Bitget 已上线 SKDD、GILD、TMF 等 9 只股票永续合约","url":"https://stock-news.laohu8.com/highlight/detail?id=2654027040","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654027040?lang=zh_cn&edition=full","pubTime":"2026-07-28 11:11","pubTimestamp":1785208272,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据官方公告，为满足用户多元化投资需求，Bitget 已上线 SKDD（2 倍做空 SK 海力士 ETF）、SKUU（2 倍做多 SK 海力士 ETF）、GILD（Gilead Sciences）、TMF（3 倍做多美国长期国债 ETF）等 9 只股票及 ETF 永续合约。\n\n上述合约均以 USDT 结算，支持最高 20 倍杠杆和 7×24 小时交易。更多详情可参阅 Bitget 官方平台。\n\n\n ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2278557","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","IBBQ","LU0122379950.USD","TMED","BK4578","LU0965509283.SGD","LU1037948541.HKD","LU0882574055.USD","IBB","LU0320765992.SGD","MEDI","BK4566","LU2324357040.USD","SG9999015952.SGD","LU0289739699.SGD","BK4532","IE00B7SZLL34.SGD","BMED","SG9999015986.USD","BIB","LU0058720904.USD","IE00B19Z3581.USD","LU0965509010.AUD","IE00B19Z3B42.SGD","LU1430594728.SGD","SG9999015945.SGD","LU0114720955.EUR","LU0965509101.SGD","LU0861579265.USD","BBH","LU1061106388.HKD","LU2112291526.USD","BK4550","GILD","LU1066053197.SGD","TBXU","BK4588","LU1934455194.USD","LU0965508806.USD","LU1674673428.USD","LU1934455863.HKD","IE0002270589.USD","LU1934455277.USD","LU1674673691.USD","LU0109394709.USD","LU1839511570.USD","SG9999015978.USD","BK4139","BK4583","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654097843","title":"Argenx(ARGX.US)豪掷22亿美元、溢价40%收购Forte Biosciences(FBRX.US) 加码布局免疫学药物组合","url":"https://stock-news.laohu8.com/highlight/detail?id=2654097843","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654097843?lang=zh_cn&edition=full","pubTime":"2026-07-27 14:52","pubTimestamp":1785135121,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0109394709.USD","IBB","IE00BJJMRZ35.SGD","FMED","IE00B4R5TH58.HKD","IE0034235188.USD","TBXU","LU0320765992.SGD","FBRX","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","ARGX","BK4139","IE00B2B36J28.USD","LU2324357040.USD","LU1983260115.SGD","BK4588","IE0009355771.USD","LU0889565916.HKD","BK4585","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653895100","title":"吉利德科学(GILD)肿瘤组合疗法获欧洲药品管理局旗下CHMP推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2653895100","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653895100?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:45","pubTimestamp":1784889935,"startTime":"0","endTime":"0","summary":"金吾财讯 | 吉利德科学 宣布，欧洲药品管理局旗下人用药品委员会已发布积极意见，建议批准其Trop-2靶向ADC药物Trodelvy联合帕博利珠单抗，用于既往未接受过全身治疗、且肿瘤PD-L1表达阳性的不可切除局部晚期或转移性三阴性乳腺癌成人患者。若欧盟委员会于2026年晚些时候正式批准该联合疗法，Trodelvy将实现从单药到联合疗法、全面覆盖不同PD-L1表达状态的mTNBC一线治疗布局。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/NmQ4YmNlMWEyMTYyODU5MDQwMjQzMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NmQ4YmNlMWEyMTYyODU5MDQwMjQzMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302998","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","MEDI","LU1037948541.HKD","CHMP","GILD","LU1571399168.USD","LU0320765992.SGD","IBBQ","SG9999015978.USD","LU0823416689.USD","SG9999015945.SGD","IE00BZ1G4Q59.USD","LU2324357040.USD","LU0965509010.AUD","LU0234570918.USD","LU0289739699.SGD","LU1585245621.USD","BK4588","TBXU","BK4550","SG9999015986.USD","LU0965509101.SGD","BBH","BIB","BK4568","BMED","IBB","LU1066051498.USD","LU1674673428.USD","LU0058720904.USD","LU1023059063.AUD","LU2468319806.SGD","TMED","BK4585","IE00BSNM7G36.USD","LU0122379950.USD","LU2089984988.USD","LU2087621335.USD","BK4583","LU0965508806.USD","IE00B19Z3581.USD","LU1061106388.HKD","LU1934455863.HKD","IE0002270589.USD","LU0889565916.HKD","LU1057294990.SGD","LU1934455194.USD","SG9999015952.SGD","BK4578","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185859812","title":"CHMP推荐吉利德Trodelvy®联合Keytruda®用于PD-(L)1阳性一线转移性三阴性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1185859812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185859812?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:29","pubTimestamp":1784888958,"startTime":"0","endTime":"0","summary":"欧洲药品管理局人用药品委员会（CHMP）近日给出推荐意见，支持吉利德科学的Trodelvy®与Keytruda®联合使用，用于治疗PD-(L)1阳性的一线转移性三阴性乳腺癌患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","LU0289739699.SGD","LU0861579265.USD","LU2087621335.USD","LU1037948897.HKD","LU1934455194.USD","BIB","LU0965509010.AUD","LU0234570918.USD","LU0889565916.HKD","LU0965509283.SGD","TMED","LU0320765992.SGD","LU0823416689.USD","BK4532","SG9999015952.SGD","LU1066053197.SGD","IBBQ","BK4583","IE00BZ1G4Q59.USD","BK4585","BBH","IBB","LU1023059063.AUD","GILD","IE00BSNM7G36.USD","IE00B19Z3581.USD","LU1037948541.HKD","SG9999015986.USD","LU1066051498.USD","IE00B19Z3B42.SGD","BK4568","BK4139","LU2324357040.USD","LU1571399168.USD","BK4550","BMED","LU0058720904.USD","LU2468319806.SGD","TBXU","BK4566","BK4588","LU0114720955.EUR","LU0882574055.USD","LU0109394709.USD","LU1934455277.USD","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU0965508806.USD","LU1839511570.USD","LU0122379950.USD","MEDI","LU0965509101.SGD","LU1674673428.USD","LU1674673691.USD","LU2112291526.USD","SG9999015978.USD","IE00BKVL7J92.USD","LU1585245621.USD","LU1934455863.HKD","LU1061106388.HKD","LU2089984988.USD","LU1778281490.HKD","IE0002270589.USD","SG9999015945.SGD","LU1057294990.SGD","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653074709","title":"百济神州/安进 FIC 双抗，皮下制剂进入 III 期","url":"https://stock-news.laohu8.com/highlight/detail?id=2653074709","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653074709?lang=zh_cn&edition=full","pubTime":"2026-07-23 19:30","pubTimestamp":1784806200,"startTime":"0","endTime":"0","summary":"7 月 22 日，药物临床试验登记与信息公示平台显示，安进和百济神州共同登记了一项在接受含铂一线化疗后的复发性广泛期小细胞肺癌试验参与者中比较 Tarlatamab皮下给药与静脉给药的 III 期研究DeLLphi-315。在皮下剂型的开发方面，安进和百济神州于 2024 年 9 月启动了一项在广泛期小细胞肺癌受试者中评价 Tarlatamab 皮下给药的安全性、耐受性、药代动力学和初步抗肿瘤活性的 Ib 期研究 DeLLphi-308。而本次启动的DeLLphi-315 研究是塔拉妥单抗皮下给药方案启动的首个 III 期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-23/doc-iniivazc5268721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0868494617.USD","688235","IBB","ONC","PBE","LU1719994722.HKD","LU1251922891.USD","PJP","LU1770034418.SGD","LU0058720904.USD","LU1983299246.USD","LU0320765992.SGD","III","SG9999001440.SGD","KURE","LU0307460666.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","LU1061106388.HKD","LU2242652126.USD","LU1571399168.USD","BK1583","BK1500","BBH","LU0588546209.SGD","IE0009355771.USD","BK1588","BK4588","BK4599","06160","IBBQ","IE0002141913.USD","BK4534","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU2112291526.USD","BK4139","LU1303224171.USD","AMGN","BIB","LU2242646821.SGD","LU0122379950.USD","LU2328871848.SGD","LU2468319806.SGD","BK4134","LU0289739699.SGD","BK4581","TBXU","BK4585","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653749341","title":"argenx(ARGX)二季度产品净销售额达15.16亿美元 同比增长60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653749341","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653749341?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:18","pubTimestamp":1784801894,"startTime":"0","endTime":"0","summary":"金吾财讯 | 全球自身免疫疾病龙头生物科技公司 argenx 发布了2026年第二季度及上半年财报。其中，2026年第二季度，公司实现产品净销售额 15.16亿美元，同比大幅增长 60%，环比增长 17%。资金储备方面，截至2026年6月30日，argenx 拥有的现金、现金等价物及流动金融资产达 52亿美元，显著高于2025年底的44亿美元，为后续临床研发及商业化扩张提供了雄厚的资金屏障。截至2026年底，argenx 预计将有10款药物分子处于临床研发阶段。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/ODM0ODU4NWZiOGY2NDQ4NTA4OTM0NDg5MTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ODM0ODU4NWZiOGY2NDQ4NTA4OTM0NDg5MTI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302939","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235188.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","BK4588","TBXU","FMED","LU0109394709.USD","BK4585","BK4139","IE00BJT1NW94.SGD","IE0009355771.USD","LU1983260115.SGD","IBB","ARGX","IE00B2B36J28.USD","LU0320765992.SGD","IE0002141913.USD","LU2324357040.USD","IE00BFTCPJ56.SGD","BK4505","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653584157","title":"创新药研发加速遇“猴荒”","url":"https://stock-news.laohu8.com/highlight/detail?id=2653584157","media":"三里河","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653584157?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:21","pubTimestamp":1784708497,"startTime":"0","endTime":"0","summary":"“要站在‘猴’里，不要像猴子一样站在那里。”资本市场从来不缺故事。近期，昭衍新药业绩暴增，原因是实验猴市场价格上涨，带动公司手里的“猴子资产”大幅增值，多家相关概念公司股价也跟风大涨。甚至有人顺藤摸瓜，挖出了“香蕉概念”。网友戏称：这是产业链挖掘最深的一次。一只猴子，为什么能扰动资本市场？答案藏在药物的研发链条里。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817277458.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817277458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LFSC","GSKH","XLVI","BIOY","APXH","IBB","GDOC","PBE","BK4585","WRND","BBP","SBIO","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169878111","title":"Leerink Partners下调吉利德科学评级至“与大盘持平”，目标价大幅调降至127美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169878111","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169878111?lang=zh_cn&edition=full","pubTime":"2026-07-21 12:03","pubTimestamp":1784606620,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners调整了对生物技术公司吉利德科学的股票评级。该机构将其评级从原先的“跑赢大盘”下调至“与大盘持平”，反映出其对该公司近期前景更为审慎的看法。\n与此同时，Leerink Partners也显著下调了吉利德科学的目标股价，从每股146美元大幅削减至127美元。这一调整意味着该机构对该公司未来股价的预期有所降低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU1023059063.AUD","BMED","IE00B19Z3B42.SGD","LU0965509010.AUD","LU1037948541.HKD","LU1066051498.USD","LU0882574055.USD","BK4550","LU1674673691.USD","BK4583","LU1585245621.USD","GILD","LU0823416689.USD","BK4578","BK4139","BK4588","IE00B19Z3581.USD","LU0234570918.USD","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","LU1430594728.SGD","LU1571399168.USD","LU2089984988.USD","SG9999015986.USD","TMED","IBBQ","LU0114720955.EUR","LU1839511570.USD","BK4532","LU1934455194.USD","LU1934455863.HKD","LU0965508806.USD","LU1061106388.HKD","LU0058720904.USD","BK4585","LU1066053197.SGD","LU0889565916.HKD","LU1037948897.HKD","LU1674673428.USD","LU0965509101.SGD","LU2087621335.USD","LU2112291526.USD","IE0002270589.USD","IE00BKVL7J92.USD","SG9999015952.SGD","LU0861579265.USD","LU1778281490.HKD","IBB","BK4566","LU2324357040.USD","BK4568","BIB","SG9999015945.SGD","IE00B3T34201.USD","IE00BSNM7G36.USD","LU1057294990.SGD","TBXU","LU0320765992.SGD","LU0965509283.SGD","LU1934455277.USD","LU2468319806.SGD","MEDI","LU0289739699.SGD","BBH","SG9999015978.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653210240","title":"Leerink下调吉利德科学目标价至127美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653210240","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653210240?lang=zh_cn&edition=full","pubTime":"2026-07-21 10:35","pubTimestamp":1784601350,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2087621335.USD","LU0289739699.SGD","LU2468319806.SGD","BK4139","IE00B19Z3B42.SGD","GILD","IE00B7SZLL34.SGD","LU1674673691.USD","BBH","LU0114720955.EUR","LU1674673428.USD","SG9999015945.SGD","LU0109394709.USD","LU1778281490.HKD","LU0234570918.USD","LU0823416689.USD","LU0882574055.USD","IE00BSNM7G36.USD","BK4583","BMED","LU0058720904.USD","IBB","LU0965509101.SGD","LU2112291526.USD","IE00BKVL7J92.USD","SG9999015978.USD","LU0320765992.SGD","IBBQ","IE00BZ1G4Q59.USD","LU1839511570.USD","LU1023059063.AUD","UDN","UUP","LU0861579265.USD","LU0965509283.SGD","LU0122379950.USD","SG9999015986.USD","LU2089984988.USD","BK4550","LU1037948541.HKD","MEDI","LU2324357040.USD","BK4578","LU0965509010.AUD","BK4585","BIB","LU0889565916.HKD","LU1066053197.SGD","LU1934455863.HKD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651495621","title":"三星生物制剂与欧加农将在澳大利亚推出新型生物类似药。","url":"https://stock-news.laohu8.com/highlight/detail?id=2651495621","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651495621?lang=zh_cn&edition=full","pubTime":"2026-07-16 04:04","pubTimestamp":1784145897,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBB","LU2272731782.SGD","LU2473716301.USD","LU2272731600.USD","PPH","BK4585","BK4588","LU2322448957.HKD","EMXC","LU1992135472.HKD","LU2322448791.USD","LU1992135399.USD","LU2272731865.HKD","XPH","IE00B5TLWC47.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651117599","title":"Vertex(VRTX)百亿美元收购罕见病药企 拓宽内分泌管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2651117599","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651117599?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:10","pubTimestamp":1783951848,"startTime":"0","endTime":"0","summary":"金吾财讯 | Vertex Pharmaceuticals 与 Crinetics Pharmaceuticals 共同披露收购协议，企业将以每股 85 美元现金完成标的全额收购，交易对应 Crinetics 整体股权价值约 100 亿美元，扣除标的账面现金后净交易对价 88 亿美元，交易预计 2026 年第三季度完成，消息落地后 Crinetics 盘后股价实现翻倍上涨。Vertex 计划依托自有现金搭配债务工具完成交易资金筹措，美国银行、摩根士丹利提供 45 亿美元全额过渡性融资，收购落地后企业罕见病内分泌赛道产品矩阵将实现大幅扩容。","market":"us","thumbnail":"https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302497","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","LU0079474960.USD","IDNA","VRTX","LU1069344957.HKD","LU1093756168.USD","LU0757428866.USD","VERX","LU2456880835.USD","IE00B19Z9Z06.USD","LU1093756325.SGD","IE00B4R5TH58.HKD","IE0002270589.USD","SG9999001176.SGD","LU1585245621.USD","IE00B894F039.SGD","LU0256863811.USD","IBB","LU2462157665.USD","BBH","LU0234570918.USD","LU0061475181.USD","LU0109394709.USD","IE00B2B36J28.USD","LU1778281490.HKD","LU2362540622.SGD","LU2362541513.USD","BK4007","SG9999001176.USD","LU0432979614.USD","IE0009355771.USD","BK4585","BIB","LU2237438978.USD","LU2417539215.USD","LU2362541273.HKD","SG9999013999.USD","IE00BJT1NW94.SGD","IE00BZ9MQY76.HKD","IE0002141913.USD","BK4588","BK4532","IE00B19Z3581.USD","LU1035775433.USD","IE00BFTCPJ56.SGD","LU1674673428.USD","LU0889565916.HKD","PBE","CRNX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183275253","title":"Pliant Therapeutics任命Flavia Borellini博士和Robert Iannone博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1183275253","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183275253?lang=zh_cn&edition=full","pubTime":"2026-07-13 20:35","pubTimestamp":1783946106,"startTime":"0","endTime":"0","summary":"临床阶段生物技术公司Pliant Therapeutics今日宣布，任命Flavia Borellini博士与Robert Iannone博士为公司董事会新成员。这两项任命为董事会注入了深厚的全球肿瘤药物开发经验，并进一步强化了其在运营与监管事务方面的专业能力。目前，除了在Pliant任职外，他还担任Autolus Therapeutics的董事会成员。关于Pliant Therapeutics, Inc.：Pliant Therapeutics是一家临床阶段的生物制药公司，专注于基于整合素的疗法的发现与开发。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4007","BK4585","IBB","R","BK4232","BK4022","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651162210","title":"英硅智能早盘涨超7% 与康哲药业达成AI+创新药研发新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651162210","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651162210?lang=zh_cn&edition=full","pubTime":"2026-07-13 10:02","pubTimestamp":1783908120,"startTime":"0","endTime":"0","summary":" 英硅智能早盘涨超7%，截至发稿，股价上涨6.21%，报45.48港元，成交额3.32亿港元。 7月13日，据英硅智能官微消息，公司宣布与康哲药业在中枢神经系统领域开展另一项AI驱动的药物发现合作。 根据合作协议，双方将结合英硅智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，双方共同推进该研发项目的合作开发。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-13/doc-inihrnpk9058117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BYV24P56.USD","QTOC","SBIO","LFSC","PBE","SG9999015978.USD","SG9999015945.SGD","VTHR","BK1191","CHAT","00867","BK4588","BK1593","IE00BVYPNQ40.USD","SG9999015986.USD","IE00BGHQDM52.EUR","ARTY","WRND","IBB","SG9999004220.SGD","IE00BMCWC346.EUR","BK4585","AIPO","GSKH","LU2488822045.USD","GDOC","IE00BVYPNP33.GBP","SG9999015952.SGD","AGIX","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650760159","title":"福泰制药百亿美元并购透露了什么讯号？","url":"https://stock-news.laohu8.com/highlight/detail?id=2650760159","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650760159?lang=zh_cn&edition=full","pubTime":"2026-07-11 22:55","pubTimestamp":1783781749,"startTime":"0","endTime":"0","summary":"01百亿美元级现金并购的底气福泰制药2025年全年营收120.01亿美元，同比增长9%，非GAAP净利润47.5亿美元，毛利率维持85%以上高位，账面现金及有价证券超过123亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1783569458583958068","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["VRTX","IE00B19Z3581.USD","IE00B2B36J28.USD","SGXZ57979304.SGD","XMMO","IBB","IE00BJJMRZ35.SGD","IE0002270589.USD","PBE","SG9999001176.SGD","BK4567","LU0823416689.USD","LU2324357040.USD","LU0109394709.USD","LU1035775433.USD","IE00B894F039.SGD","LU0058720904.USD","LU0320765992.SGD","IE00BZ9MQY76.HKD","LU1093756168.USD","LU1778281490.HKD","IE00B4R5TH58.HKD","LU0234570918.USD","LU2236285917.USD","CALF","BBH","BK4532","LU2417539215.USD","IDNA","IE0009355771.USD","BK4588","IBBQ","SG9999001176.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0061475181.USD","MYLD","LU1069344957.HKD","BK4139","LU1093756325.SGD","BIB","LU2362540622.SGD","IE00B19Z9Z06.USD","LU1585245621.USD","LU0289739699.SGD","KCE","IE00B19Z9P08.USD","LU2462157665.USD","LU0079474960.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649299398","title":"大摩解读福泰制药百亿收购Crinetics：补齐内分泌管线布局 两大核心药物打开增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2649299398","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649299398?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:01","pubTimestamp":1783512080,"startTime":"0","endTime":"0","summary":"摩根士丹利发布研报，对福泰制药以100亿美元收购Crinetics的交易进行解读。此次收购将为福泰制药新增第五大业务支柱——内分泌药物，补齐公司管线布局。根据公告，每股85美元的收购价格较Crinetics周一的收盘价溢价了102%。值得注意的是，摩根士丹利担任福泰制药的财务顾问，协助该公司达成收购Crinetics的协议。","market":"us","thumbnail":"https://community-static.tradeup.com/news/7870ada20f73cf52a4a0efa576cd369c","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/7870ada20f73cf52a4a0efa576cd369c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464871.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"大摩解读福泰制药(VRTX.US)百亿收购Crinetics：补齐内分泌管线布局 两大核心药物打开增长空间","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","LU2237438978.USD","IBBQ","LU2362540622.SGD","LU0528227936.USD","LU2111349929.HKD","LU1585245621.USD","BBH","IE0009355771.USD","BK4533","LU1732799900.SGD","SG9999001176.USD","IDNA","LU2133065610.SGD","LU0210528500.USD","LU0109394709.USD","LU0053666078.USD","IE00B894F039.SGD","LU0098860793.USD","LU2089284900.SGD","LU0079474960.USD","LU2236285917.USD","IBB","IAI","LU0058720904.USD","LU0432979614.USD","LU1720051017.SGD","VRTX","KBWB","LU1720051108.HKD","LU2362541273.HKD","BK4581","IE00B19Z3581.USD","LU0823416689.USD","PBE","BIB","LU1791710400.SGD","LU1244550221.USD","IE0002141913.USD","IE0002270589.USD","IE00B19Z9P08.USD","LU2487616109.SGD","LU0390134368.USD","LU1674673691.USD","LU2456880835.USD","LU0882574139.USD","BK4139","LU1363072403.SGD","LU0267386448.USD","IE00BZ9MQY76.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":-0.0012},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.1017},{"period":"1year","weight":0.4208},{"period":"ytd","weight":0.1256}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":-0.0068},{"period":"3month","weight":0.0292},{"period":"6month","weight":0.0719},{"period":"1year","weight":0.169},{"period":"ytd","weight":0.0876}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"安硕纳斯达克生物科技ETF追踪纳斯达克生物医疗指数(Biotechnology Index)。Biotechnology Index包含的标的为在纳斯达克上市的生物医疗公司。\n风险提示：标的成分和权重，有可能随着时间的迁移而发生变化。","yearOnYearQuotes":[{"month":1,"riseRate":0.722222,"avgChangeRate":0.019108},{"month":2,"riseRate":0.611111,"avgChangeRate":-0.001245},{"month":3,"riseRate":0.555556,"avgChangeRate":0.002788},{"month":4,"riseRate":0.5,"avgChangeRate":0.003638},{"month":5,"riseRate":0.611111,"avgChangeRate":0.009102},{"month":6,"riseRate":0.777778,"avgChangeRate":0.027534},{"month":7,"riseRate":0.722222,"avgChangeRate":0.036687},{"month":8,"riseRate":0.470588,"avgChangeRate":-0.000694},{"month":9,"riseRate":0.411765,"avgChangeRate":-0.000938},{"month":10,"riseRate":0.388889,"avgChangeRate":-0.014563},{"month":11,"riseRate":0.833333,"avgChangeRate":0.040881},{"month":12,"riseRate":0.555556,"avgChangeRate":0.007272}],"exchange":"NASDAQ","name":"生物科技指数ETF-iShares Nasdaq","nameEN":"iShares Biotechnology ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技指数ETF-iShares Nasdaq(IBB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技指数ETF-iShares Nasdaq(IBB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技指数ETF-iShares Nasdaq,IBB,生物科技指数ETF-iShares Nasdaq股票,生物科技指数ETF-iShares Nasdaq股票老虎,生物科技指数ETF-iShares Nasdaq股票老虎国际,生物科技指数ETF-iShares Nasdaq行情,生物科技指数ETF-iShares Nasdaq股票行情,生物科技指数ETF-iShares Nasdaq股价,生物科技指数ETF-iShares Nasdaq股市,生物科技指数ETF-iShares Nasdaq股票价格,生物科技指数ETF-iShares Nasdaq股票交易,生物科技指数ETF-iShares Nasdaq股票购买,生物科技指数ETF-iShares Nasdaq股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技指数ETF-iShares Nasdaq(IBB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技指数ETF-iShares Nasdaq(IBB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}